Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?

Ibrutinib is a novel oral covalent inhibitor of Bruton's tyrosine kinase (BTK). It has been approved for the treatment of relapsing chronic lymphocytic leukemia (CLL), or CLL with high-risk cytogenetic abnormalities. Several cases of invasive aspergillosis have recently been reported in ibrutin...

Full description

Saved in:
Bibliographic Details
Published in:Médecine et maladies infectieuses 2018-06, Vol.48 (4), p.294-297
Main Authors: Gaye, E., Le Bot, A., Talarmin, J.P., Le Calloch, R., Belaz, S., Dupont, M., Tattevin, P.
Format: Article
Language:English
Subjects:
Aged
Aspergillose cérébrale
Brain Diseases - chemically induced
Brain Diseases - microbiology
Cancer
Cerebral aspergillosis
Chronic lymphocytic leukemia
Human health and pathology
Humans
Ibrutinib
Infectious diseases
Leucémie lymphoïde chronique
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Life Sciences
Male
Neuroaspergillosis - chemically induced
Opportunistic Infections - chemically induced
Pharmaceutical sciences
Pharmacology
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ibrutinib is a novel oral covalent inhibitor of Bruton's tyrosine kinase (BTK). It has been approved for the treatment of relapsing chronic lymphocytic leukemia (CLL), or CLL with high-risk cytogenetic abnormalities. Several cases of invasive aspergillosis have recently been reported in ibrutinib-treated patients. We report two cases of cerebral aspergillosis in CLL patients treated with ibrutinib.
ISSN:0399-077X
1769-6690
DOI:10.1016/j.medmal.2018.01.003